161 – 170 of 304
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
-
Mark
Cerebrospinal fluid/plasma quotients of essential and non-essential metals in patients with Alzheimer's disease
(
- Contribution to journal › Article
- 2010
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
BACE1 gene variants do not influence BACE1 activity, levels of APP or A beta isoforms in CSF in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association of the RAGE G82S polymorphism with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
A beta 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.
(
- Contribution to journal › Article
-
Mark
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
(
- Contribution to journal › Article